Phagos

Executive Summary

Phagos is a French biotech company at the forefront of developing bacteriophage therapy to address the escalating global crisis of antimicrobial resistance (AMR). Traditional antibiotics are becoming increasingly ineffective against multidrug-resistant pathogens, creating an urgent need for novel solutions. Phagos leverages naturally occurring viruses called bacteriophages that specifically target and lyse pathogenic bacteria. Their approach uses rationally designed phage cocktails to precisely eliminate harmful bacteria while sparing the beneficial microbiome, a key advantage over broad-spectrum antibiotics that disrupt microbial balance and contribute to resistance. This targeted strategy has the potential to treat chronic infections, such as those caused by Pseudomonas aeruginosa and Staphylococcus aureus, which are leading causes of morbidity in healthcare settings. Founded in 2021, Phagos is currently in the preclinical stage, focusing on validating its phage cocktail platform through in vitro and in vivo studies. The company operates with a lean team of experts in phage biology, microbiology, and drug development. While still early-stage, Phagos has attracted attention as a promising European startup to watch in 2026, as indicated by its inclusion in European Biotechnology's list. Success will depend on achieving key preclinical milestones, securing further funding (the company has not publicly disclosed total raised), and navigating regulatory pathways for phage therapeutics. If successful, Phagos could offer a powerful weapon against AMR, providing a sustainable alternative to conventional antibiotics and reducing the burden of hard-to-treat infections.

Upcoming Catalysts (preview)

• Q3 2026Completion of Key Preclinical Efficacy Studies in Animal Models65% success
• Q4 2026Series A Financing Round50% success
• Q1 2027Regulatory Submission for First-in-Human Clinical Trial40% success